Instem completed the acquisition of d-Wise Technologies for $31m.

Instem, a provider of IT solutions to the global life sciences market, completed the acquisition of d-Wise Technologies, a US-based clinical trial technology and consulting firm, for $31m. "We believe that the enlarged Group is now even closer to becoming a one-stop-shop for life science companies looking for a long-term relationship as we assist them across the drug discovery and development landscape. We have known d-wise for nearly a decade and have been impressed with their growth, as well as the position they have developed as highly trusted thought leaders in clinical trial analysis and regulatory submission technology," Phil Reason, Instem CEO.